Cover Image

Update breast cancer 2020 part 5 - moving therapies from advanced to early breast cancer patients = Update Mammakarzinom 2020 Teil 5 – Einführung von Substanzen aus der metastasierten Therapiesituation in die frühe Therapiesituation

In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: Lux, Michael Patrick (Author) , Schneeweiss, Andreas (Author) , Hartkopf, Andreas (Author) , Müller, Volkmar (Author) , Janni, Wolfgang (Author) , Belleville, Erik (Author) , Stickeler, Elmar (Author) , Thill, Marc (Author) , Fasching, Peter Andreas (Author) , Kolberg, Hans-Christian (Author) , Untch, Michael (Author) , Harbeck, Nadia (Author) , Wöckel, Achim (Author) , Thomssen, Christoph (Author) , Schulmeyer, Carla (Author) , Welslau, Manfred (Author) , Overkamp, Friedrich (Author) , Schütz, Florian (Author) , Lüftner, Diana (Author) , Ditsch, Nina (Author)
Format: Article (Journal)
Language:English
Published: 2021-04-14
In: Geburtshilfe und Frauenheilkunde
Year: 2021, Volume: 81, Issue: 04, Pages: 469-480
ISSN:1438-8804
DOI:10.1055/a-1397-7170
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1055/a-1397-7170
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1397-7170
Get full text
Author Notes:Michael P. Lux, Andreas Schneeweiss, Andreas D. Hartkopf, Volkmar Müller, Wolfgang Janni, Erik Belleville, Elmar Stickeler, Marc Thill, Peter A. Fasching, Hans-Christian Kolberg, Michael Untch, Nadia Harbeck, Achim Wöckel, Christoph Thomssen, Carla E. Schulmeyer, Manfred Welslau, Friedrich Overkamp, Florian Schütz, Diana Lüftner, Nina Ditsch
Description
Summary:In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.
Item Description:Gesehen am 14.07.2021
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1397-7170

Similar Items